HIV prevalence, testing and treatment among men who have sex with men through engagement in virtual sexual networks in Kenya: a cross-sectional bio-behavioural study.
Adult
Anti-Retroviral Agents
/ therapeutic use
Continuity of Patient Care
Cross-Sectional Studies
HIV Infections
/ diagnosis
Homosexuality, Male
/ statistics & numerical data
Humans
Internet
Kenya
/ epidemiology
Logistic Models
Male
Prevalence
Sexual Partners
Sexual and Gender Minorities
Surveys and Questionnaires
Unsafe Sex
Young Adult
HIV care continuum
HIV prevalence
HIV testing
Kenya
men who have sex with men
virtual networks
Journal
Journal of the International AIDS Society
ISSN: 1758-2652
Titre abrégé: J Int AIDS Soc
Pays: Switzerland
ID NLM: 101478566
Informations de publication
Date de publication:
06 2020
06 2020
Historique:
received:
19
09
2019
revised:
06
04
2020
accepted:
23
04
2020
entrez:
27
6
2020
pubmed:
27
6
2020
medline:
7
4
2021
Statut:
ppublish
Résumé
In Kenya, men who have sex with men (MSM) are increasingly using virtual sites, including web-based apps, to meet sex partners. We examined HIV testing, HIV prevalence, awareness of HIV-positive status and linkage to antiretroviral therapy (ART), for HIV-positive MSM who solely met partners via physical sites (PMSM), compared with those who did so in virtual sites (either solely via virtual sites (VMSM), or via both virtual and physical sites (DMSM)). We conducted a cross-sectional bio-behavioural survey of 1200 MSM, 15 years and above, in three counties in Kenya between May and July 2019, using random sampling of physical and virtual sites. We classified participants as PMSM, DMSM and VMSM, based on where they met sex partners, and compared the following between groups using chi-square tests: (i) proportion tested; (ii) HIV prevalence and (iii) HIV care continuum among MSM living with HIV. We then performed multivariable logistic regression to measure independent associations between network engagement and HIV status. 177 (14.7%), 768 (64.0%) and 255 (21.2%), of participants were classified as PMSM, DMSM and VMSM respectively. 68.4%, 70.4% and 78.5% of PMSM, DMSM and VMSM, respectively, reported an HIV test in the previous six months. HIV prevalence was 8.5% (PMSM), 15.4% (DMSM) and 26.7% (VMSM), p < 0.001. Among those living with HIV, 46.7% (PMSM), 41.5% (DMSM) and 29.4% (VMSM) were diagnosed and aware of their status; and 40.0%, 35.6% and 26.5% were on antiretroviral treatment. After adjustment for other predictors, MSM engaged in virtual networks remained at a two to threefold higher risk of prevalent HIV: VMSM versus PMSM (adjusted odds ratio 3.88 (95% confidence interval (CI) 1.84 to 8.17) p < 0.001); DMSM versus PMSM (2.00 (95% CI 1.03 to 3.87), p = 0.040). Engagement in virtual networks is associated with elevated HIV risk, irrespective of individual-level risk factors. Understanding the difference in characteristics among MSM-seeking partners in different sites will help HIV programmes to develop subpopulation-specific interventions.
Identifiants
pubmed: 32589341
doi: 10.1002/jia2.25516
pmc: PMC7319161
doi:
Substances chimiques
Anti-Retroviral Agents
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e25516Subventions
Organisme : Bill & Melinda Gates Foundation
ID : OPP-11191068
Pays : United States
Organisme : CIHR
Pays : Canada
Informations de copyright
© 2020 The Authors. Journal of the International AIDS Society published by John Wiley & Sons Ltd on behalf of the International AIDS Society.
Références
Biomed Res Int. 2016;2016:2860346
pubmed: 28105415
Sex Transm Infect. 2012 Aug;88(5):357-62
pubmed: 22332149
Sex Transm Infect. 2013 Nov;89(7):595-601
pubmed: 23723251
PLoS One. 2014 Jan 23;9(1):e86603
pubmed: 24466166
J Med Internet Res. 2017 Nov 24;19(11):e394
pubmed: 29175811
AIDS Behav. 2017 Nov;21(11):3068-3077
pubmed: 27233248
PLoS One. 2019 May 31;14(5):e0217501
pubmed: 31150447
Arch Sex Behav. 2011 Aug;40(4):803-16
pubmed: 20809373
AIDS Behav. 2011 Apr;15 Suppl 1:S88-90
pubmed: 21331800
PLoS One. 2009;4(3):e4997
pubmed: 19325707
J Acquir Immune Defic Syndr. 2018 Apr 15;77(5):459-466
pubmed: 29280767
Sex Transm Dis. 2008 Aug;35(8):746-52
pubmed: 18650772
Glob Health Action. 2014 Oct 23;7:24814
pubmed: 25361722
Sex Transm Infect. 2014 May;90(3):237-42
pubmed: 24337729
J Acquir Immune Defic Syndr. 2017 Nov 1;76(3):241-249
pubmed: 28746167
PLoS One. 2012;7(3):e32915
pubmed: 22427908
J Med Internet Res. 2015 May 25;17(5):e129
pubmed: 26006788
AIDS Care. 2017 Jan;29(1):98-104
pubmed: 27329745
BMC Public Health. 2014 May 26;14:508
pubmed: 24885058
Arch Sex Behav. 2006 Aug;35(4):473-81
pubmed: 16933107
BMC Public Health. 2019 Jul 23;19(1):986
pubmed: 31337368
J Med Internet Res. 2019 Jan 21;21(1):e10171
pubmed: 30664490
Lancet. 2016 Jul 9;388(10040):198-206
pubmed: 27411880
BMC Public Health. 2018 Mar 20;18(1):370
pubmed: 29554867
Int J Epidemiol. 2010 Aug;39(4):1048-63
pubmed: 20406794
Clin Chem. 2020 Mar 1;66(3):406-407
pubmed: 32109297
PLoS One. 2012;7(2):e31072
pubmed: 22348038
AIDS Behav. 2014 Aug;18(8):1428-35
pubmed: 24077974
AIDS Behav. 2015 Mar;19(3):561-74
pubmed: 25103866
BMC Infect Dis. 2018 Aug 6;18(1):368
pubmed: 30081839
J Acquir Immune Defic Syndr. 2017 Jul 1;75 Suppl 3:S288-S295
pubmed: 28604430
Sex Transm Infect. 2004 Dec;80(6):455-8
pubmed: 15572613
Sex Transm Dis. 2005 Oct;32(10 Suppl):S48-52
pubmed: 16205293
AIDS. 2015 Dec;29 Suppl 3:S201-10
pubmed: 26565965
J Behav Med. 2008 Dec;31(6):463-77
pubmed: 18770021